Lan Bin, Luo Chao, Pocha Christine, Wang Qing, Tan Jie
Department of Interventional Vascular Surgery, Hunan Provincial People's Hospital (The First Affiliated Hospital of Hunan Normal University), Changsha, China.
Avera Hepatology and Transplant Institute, University of South Dakota, Sioux Falls, SD, USA.
J Gastrointest Oncol. 2024 Dec 31;15(6):2599-2612. doi: 10.21037/jgo-2024-850. Epub 2024 Dec 27.
Hepatocellular carcinoma (HCC) constitutes approximately 75-85% of primary liver cancers and is a heavy burden on public health. Many innovative prediction systems have integrated radiomics, artificial intelligence, pathological information, or even genetic information for the stratification and prognosis prediction of patients with HCC. However, these systems still lack practical and clinical applications. Classical HCC staging systems remain the mainstream tool for stratification and prediction of treatment efficacy to date; although, variable characteristics and emphases between different classical HCC staging systems render its clinical selection inconsistent and therefore may be unreliable. In this study, we aimed to compare the predictive performance of classical liver cancer staging systems, including China Liver Cancer (CNLC), Barcelona Clinic Liver Cancer (BCLC), Hong Kong Liver Cancer (HKLC), modified Japanese Integrated Staging (mJIS), modified Cancer of the Liver Italian Program (mCLIP), and Tumor-Node-Metastasis (TNM) staging system, for the efficacy and prognosis of transcatheter arterial chemoembolization (TACE) in HCC patients.
A total of 148 patients with HCC who received TACE as the initial therapy between 02/01/2019 and 08/31/2022 were retrospectively included. Patients' clinical information, laboratory and imaging data, were collected. Cox regression analysis was applied to identify independent risk factors for progression-free survival (PFS) and overall survival (OS). Six liver cancer staging systems, including the CNLC, BCLC, HKLC, mJIS, mCLIP, and TNM staging system, were applied for the staging of every enrolled patient. The PFS and OS of patients with HCC following initial TACE in different staging systems were assessed, and the predictive performance of different systems was evaluated using the concordance index.
The presence of portal vein tumor thrombus (PVT), alpha fetoprotein (AFP) ≥400 ng/mL, and ineffective initial TACE treatment were independent risk factors for overall disease progression, while the presence of PVT and ineffective initial TACE treatment were independent risk factors for death. In the prediction of PFS and OS, CNLC, BCLC, HKLC, mJIS, and mCLIP all showed good predictive ability, but the predictive ability of the TNM staging system was relatively poor.
The CNLC, BCLC, HKLC, mJIS, and mCLIP staging systems provide comparable predictive value for the prognosis after the initial TACE, while the TNM staging system has poor predictive ability due to its exclusion of hepatic function.
肝细胞癌(HCC)约占原发性肝癌的75%-85%,是公共卫生的沉重负担。许多创新的预测系统已整合了放射组学、人工智能、病理信息甚至基因信息,用于HCC患者的分层和预后预测。然而,这些系统仍缺乏实际的临床应用。经典的HCC分期系统至今仍是分层和预测治疗疗效的主流工具;尽管如此,不同经典HCC分期系统之间的可变特征和重点使得其临床选择不一致,因此可能不可靠。在本研究中,我们旨在比较经典肝癌分期系统,包括中国肝癌(CNLC)、巴塞罗那临床肝癌(BCLC)、香港肝癌(HKLC)、改良日本综合分期(mJIS)、改良意大利肝癌计划(mCLIP)和肿瘤-淋巴结-转移(TNM)分期系统,对HCC患者经动脉化疗栓塞(TACE)疗效和预后的预测性能。
回顾性纳入2019年2月1日至2022年8月31日期间共148例接受TACE作为初始治疗的HCC患者。收集患者的临床信息、实验室和影像学数据。应用Cox回归分析确定无进展生存期(PFS)和总生存期(OS)的独立危险因素。应用包括CNLC、BCLC、HKLC、mJIS、mCLIP和TNM分期系统在内的六种肝癌分期系统对每例入组患者进行分期。评估不同分期系统中初始TACE治疗后HCC患者的PFS和OS,并使用一致性指数评估不同系统的预测性能。
门静脉癌栓(PVT)的存在、甲胎蛋白(AFP)≥400 ng/mL以及初始TACE治疗无效是总体疾病进展的独立危险因素,而PVT的存在和初始TACE治疗无效是死亡的独立危险因素。在PFS和OS的预测中,CNLC、BCLC、HKLC、mJIS和mCLIP均显示出良好的预测能力,但TNM分期系统的预测能力相对较差。
CNLC、BCLC、HKLC、mJIS和mCLIP分期系统对初始TACE后的预后具有可比的预测价值,而TNM分期系统由于排除了肝功能,预测能力较差。